Innovent's Byvasda (biosimilar- bevacizumab) Receives NMPA's Approval for the Treatment of Adult Recurrent Glioblastoma
Shots:
- The indication is the third indication approved for the therapy- previously it was approved for advanced NSCLC and metastatic colorectal cancer
- The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
- Byvasda is an anti -VEGF humanized mAb. In Jan’2020- Innovent out-licensed the commercial rights of the biosimilar in the US and Canada to Coherus BioSciences
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
